Myositis
Trigger and Risk Factors
Epidemiology
Introduction to Dermatomyositis
Silica dust, heavy metal, solvents may contribute to myositis with lung involvement
Exposures to silica dust, solvents or heavy metals increase the likelihood of developing various forms of myositis, especially more severe forms involving the lungs, according to data published in Arthritis Care & Research.
CAR T therapy shows ‘no major hematotoxicites’ in autoimmune disease phase 1/2 study
WASHINGTON — A phase 1/2 study of CD19 chimeric antigen receptor T-cell therapy in lupus and other autoimmune diseases demonstrated significant response with minimal toxicities, according to data presented at ACR Convergence 2024.
CD19 CAR-T therapy yields long-term benefits in lupus, myositis, systemic sclerosis
WASHINGTON — CD19 chimeric antigen receptor T-cell therapy led to remission, or ceased disease progression, over a period of up to 15 months in 35 patients with lupus, myositis and systemic sclerosis, according to data.
CAR T-cell therapy remains the 'hottest story' in lupus, autoimmune disease
DESTIN, Fla. — Positive results for chimeric antigen receptor T-cell therapy in systemic sclerosis and myositis have added fuel to the fire of recent landmark data in lupus, said a speaker at the Congress of Clinical Rheumatology East.
A rare day for rare diseases: Latest data and findings for Rare Disease Day
It’s not too often one sees Feb. 29 on the calendar, which makes it a perfect time for Rare Disease Day, dedicated to recognizing conditions that, in the words of the European Commission on Public Health, require “special combined efforts.”
Imaging, functional tests can help ‘tease out’ fast vs slow myositis progressors
SAN DIEGO — Imaging and symptom rating scales offer physicians ample opportunity to follow patients with suspected myositis and “tease out” fast vs. slow progressors, noted a speaker at the 2023 Congress of Clinical Rheumatology West.
FDA clears way for CAR T-cell therapy trial in patients with myositis
The FDA has granted an investigational new drug application for CABA-201, a 4-1BB-containing fully human CD19-CAR T-cell therapy, to be studied in patients with myositis, according to a press release from the manufacturer.